# Taiwan Liposome Company, Ltd. (TLC)

Source: https://www.quantisnow.com/company/TLC
Generated: 2026-11-11T06:10:22.260Z

- Ticker: TLC
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Major Pharmaceuticals
- IPO year: 2018
- Website: tlcbio.com

## About

Taiwan Liposome Company, Ltd., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of nanomedicines that combine its proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). The BioSeizer lipid formulation technology is designed to enable local sustained release and fast onset of APIs at the site of disease or injury with enhanced pharmacokinetic (PK) control by customization of lipid layers; and NanoX active drug loading technology enables the potential for reduced dosing frequency and enhanced distribution of liposome-encapsulated APIs to the desired site. Its lead product candidate is TLC599, an intraarticular injectable BioSeizer formulation of the API steroid dexamethasone sodium phosphate (DSP), which is in Phase III clinical trial for the treatment of knee osteoarthritis pain. The company's product candidates also comprise TLC590, a non-opioid BioSeizer formulation of the API ropivacaine that has completed Phase II clinical trial to treat post-surgical pain; TLC399, a multilamellar and multivesicular BioSeizer formulation of DSP, which is in Phase II clinical trial for ophthalmology indications; TLC178, an API that is in Phase I/II dose escalation trial to treat rhabdomyosarcoma; and TLC19 that is in Phase I clinical trial to treat COVID-19.Taiwan Liposome Company, Ltd. was founded in 1997 and is headquartered in Taipei, Taiwan.

## Latest TLC news and filings

- 2022-06-13 10:30 UTC [TLC Announces TLC599 Agreement with Endo](https://www.quantisnow.com/insight/tlc-announces-tlc599-agreement-with-endo-3018654)
- 2022-03-07 09:57 UTC [TLC BioSciences Announces Publication of TLC599 Phase II Results in Arthritis Research & Therapy](https://www.quantisnow.com/insight/tlc-biosciences-announces-publication-of-tlc599-phase-ii-results-in-2529199)
- 2022-01-08 01:15 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-taiwan-liposome-company-ltd-2231810)
- 2021-11-12 11:05 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-taiwan-liposome-company-ltd-1998532)
- 2021-10-20 20:08 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-taiwan-liposome-company-ltd-1896510)
- 2021-10-15 00:58 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1878137)
- 2021-10-08 20:00 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1858115)
- 2021-10-08 15:56 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1857393)
- 2021-09-20 20:03 UTC [SEC Form 25 filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-25-filed-by-taiwan-liposome-company-ltd-1789760)
- 2021-09-15 20:01 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1776616)
- 2021-09-15 15:56 UTC [SEC Form F-X] [SEC Form F-X filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-f-x-filed-by-taiwan-liposome-company-ltd-1775684)
- 2021-09-08 20:10 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1751877)
- 2021-09-08 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1751694)
- 2021-09-08 08:40 UTC [Public Offering] [TLC Announces Voluntary Delisting and Deregistration of American Depositary Shares](https://www.quantisnow.com/insight/tlc-announces-voluntary-delisting-and-deregistration-of-american-depositary-shares-1747922)
- 2021-09-07 20:08 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1746674)
- 2021-08-26 20:10 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1713205)
- 2021-08-26 20:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1713064)
- 2021-08-24 20:02 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1703583)
- 2021-08-20 20:06 UTC [SEC Schedule 13D] [SEC Form SC 13D/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-sc-13da-filed-by-taiwan-liposome-company-ltd-1693997)
- 2021-08-12 14:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1661936)
- 2021-08-12 09:44 UTC [TLC Reports Second Quarter 2021 Financial Results and Provides Business Update](https://www.quantisnow.com/insight/tlc-reports-second-quarter-2021-financial-results-and-provides-business-1659546)
- 2021-08-06 16:49 UTC [SEC Form CB/A filed by Taiwan Liposome Company, Ltd. (Amendment)](https://www.quantisnow.com/insight/sec-form-cba-filed-by-taiwan-liposome-company-ltd-amendment-1638428)
- 2021-08-05 18:56 UTC [SEC Form F-X] [SEC Form F-X filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-f-x-filed-by-taiwan-liposome-company-ltd-1632313)
- 2021-08-05 18:37 UTC [SEC Form CB filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-cb-filed-by-taiwan-liposome-company-ltd-1632261)
- 2021-08-04 13:14 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1618193)
- 2021-07-22 10:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1454590)
- 2021-07-15 20:02 UTC [SEC Schedule 13D] [SEC Form SC 13D filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-sc-13d-filed-by-taiwan-liposome-company-ltd-1384621)
- 2021-07-13 11:44 UTC [Analyst Downgrade] [Taiwan Liposome downgraded by H.C. Wainwright with a new price target](https://www.quantisnow.com/insight/taiwan-liposome-downgraded-by-hc-wainwright-with-a-new-price-1340889)
- 2021-07-08 10:03 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1290882)
- 2021-07-07 21:18 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1286959)
- 2021-07-07 11:42 UTC [Analyst Downgrade] [Taiwan Liposome downgraded by Laidlaw](https://www.quantisnow.com/insight/taiwan-liposome-downgraded-by-laidlaw-1275212)
- 2021-07-06 10:43 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-1257526)
- 2021-07-05 10:16 UTC [Public Offering] [TLC Announces Details of Stock Swap Transactions](https://www.quantisnow.com/insight/tlc-announces-details-of-stock-swap-transactions-1251737)
- 2021-05-28 10:58 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-888925)
- 2021-05-26 08:30 UTC [TLC and Zydus Enter Agreement to Launch AmphoTLC™ in India](https://www.quantisnow.com/insight/tlc-and-zydus-enter-agreement-to-launch-amphotlc-in-india-849433)
- 2021-05-25 09:05 UTC [TLC Announces Approval of New Drug Application of Liposomal Amphotericin B in India](https://www.quantisnow.com/insight/tlc-announces-approval-of-new-drug-application-of-liposomal-amphotericin-831822)
- 2021-05-23 13:00 UTC [Conference Announcement] [InspirMed Highlights Encouraging Data on ISPM21 and ISPM19 – Inhalable Liposome Formulations of Antiviral Drugs for COVID-19](https://www.quantisnow.com/insight/inspirmed-highlights-encouraging-data-on-ispm21-and-ispm19-inhalable-liposome-813022)
- 2021-05-14 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Taiwan Liposome Company, Ltd.](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-taiwan-liposome-company-ltd-742401)
- 2021-05-03 09:15 UTC [TLC Earns Highest Ranking in Corporate Governance Evaluation Seven Years Running](https://www.quantisnow.com/insight/tlc-earns-highest-ranking-in-corporate-governance-evaluation-seven-years-682720)
- 2021-04-26 09:30 UTC [Conference Announcement] [InspirMed to Present at the 23rd International Society for Aerosols in Medicine (ISAM) Congress](https://www.quantisnow.com/insight/inspirmed-to-present-at-the-23rd-international-society-for-aerosols-650559)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TLC
- Earnings history: https://www.quantisnow.com/earnings/TLC
- Dividend history: https://www.quantisnow.com/dividends/TLC
- Insider transactions: https://www.quantisnow.com/insiders/TLC
- Options chain: https://www.quantisnow.com/options/TLC
- SEC 8-K filings only: https://www.quantisnow.com/company/TLC/8-k
- RSS and alerts for TLC: https://www.quantisnow.com/docs/rss-feeds.md